<DOC>
	<DOCNO>NCT00006474</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine temozolomide O6-benzylguanine treating patient newly diagnose , recurrent , progressive anaplastic glioma .</brief_summary>
	<brief_title>Temozolomide O6-benzylguanine Treating Patients With Newly Diagnosed , Recurrent , Progressive Anaplastic Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose O6-benzylguanine ( O6-BG ) effective produce complete suppression tumor O6-alkylguanine-DNA alkyltransferase activity patient newly diagnose ( closed accrual 12/19/2000 ) recurrent progressive cerebral anaplastic glioma . - Determine maximum tolerate dose temozolomide administer O6-BG patient . - Determine toxicity regimen patient . - Determine anti-tumor response patient treat regimen . OUTLINE : This dose-escalation , multicenter study . - Part I : Patients receive escalate dos O6-benzylguanine ( O6-BG ) IV continuously 49 hour dose produce target depletion tumor O6-alkylguanine-DNA alkyltransferase ( AGT ) determine . Patients undergo craniotomy completion O6-BG infusion . ( close accrual 12/19/2000 ) - Part II : After determination O6-BG dose Part I , patient recurrent malignant glioma receive O6-BG IV continuously 49 hour begin day 1 . Patients also receive oral temozolomide day 1 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 20-30 patient ( 14 patient participate Part II ) accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Part I : Histologically confirm , newly diagnose glioblastoma multiforme anaplastic astrocytoma ( close accrual 12/19/2000 ) Parts I II : Histologically confirm astrocytic , oligodendroglial , mixed glial tumor Grade III higher Recurrent progressive radiotherapy Evaluable residual disease contrastenhanced MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT great 2.5 time upper limit normal Bilirubin normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min BUN great 25 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior biologic therapy recover Chemotherapy : At least 2 week since prior chemotherapy ( include limit topotecan ) recover Patients trial one follow treatment combination allow enroll 6 week receive carmustine ( BCNU ) : BCNU day 1 BCNU day 1 topotecan day 1 , 8 , 15 , 22 , 29 , 36 BCNU day 1 irinotecan day 1 , 8 , 15 , 22 Endocrine therapy : Patients corticosteroid must stable dose least 2 week study At least 6 week since prior endocrine therapy recover Radiotherapy : See Disease Characteristics At least 6 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>